Last reviewed · How we verify

ADS-5102 — Competitive Intelligence Brief

ADS-5102 (ADS-5102) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NMDA receptor antagonist / dopamine agonist. Area: Neurology.

phase 3 NMDA receptor antagonist / dopamine agonist NMDA receptor, dopamine pathways Neurology Small molecule Live · refreshed every 30 min

Target snapshot

ADS-5102 (ADS-5102) — Adamas Pharmaceuticals, Inc.. ADS-5102 is an extended-release formulation of amantadine that provides sustained dopaminergic and anti-glutamatergic activity to reduce involuntary movements.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ADS-5102 TARGET ADS-5102 Adamas Pharmaceuticals, Inc. phase 3 NMDA receptor antagonist / dopamine agonist NMDA receptor, dopamine pathways

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NMDA receptor antagonist / dopamine agonist class)

  1. Adamas Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ADS-5102 — Competitive Intelligence Brief. https://druglandscape.com/ci/ads-5102. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: